Physician profile
Gregory Burton
NPI 1215913660
$1,914.99
in general payments reported to CMS, 2019-2025
18 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $114 · 2021: $56.85 · 2023: $115 · 2024: $371 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $254.88 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $242.91 | 2019 | |
| Janssen Pharmaceuticals, INC | $237.51 | 2019 | |
| Novo Nordisk INC | $229.54 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $133.05 | 2019 | |
| Neurocrine Biosciences, INC. | $124.05 | 2019-2025 | |
| Kyowa Kirin, INC. | $120.20 | 2025 | |
| Alexion Pharmaceuticals, INC. | $116.15 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $100.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $75.48 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $63.62 | 2019 | |
| Saol Therapeutics INC. | $58.95 | 2019 | |
| Collegium Pharmaceutical, INC. | $49.11 | 2019-2020 | |
| Grt US Holding, INC. | $40.61 | 2021 | |
| Merz North America, INC. | $20.27 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16.61 | 2019 | |
| Merz Pharmaceuticals, LLC | $16.24 | 2021 | |
| Avanir Pharmaceuticals, INC. | $15.81 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Burton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.